affiliate disclosure · We earn affiliate commission on some vendor links. Audits, scores, and rankings are independent — vendors do not pay for placement and do not see drafts. read more →
Eli Lilly's Phase 3 retatrutide program reads out across the TRIUMPH-1 through TRIUMPH-5 trials. Here is what the published Phase 3 data shows so far, what it does not show, and what changes if the FDA submission proceeds in 2026.
The published TRIUMPH Phase 3 program readouts (TRIUMPH-1 through TRIUMPH-5) as available in NEJM, JAMA, and Lancet through April 2026; the corresponding ClinicalTrials.gov NCT entries (NCT05882045, NCT05952713, NCT05882187, NCT05996731, and the TRIUMPH-5 record); Eli Lilly's quarterly earnings calls and investor presentations referencing the retatrutide program from 2025–2026; and the FDA advisory-committee briefing documents posted publicly to date. This is a literature read, not a clinical-practice synthesis or a buyer's guide.
The TRIUMPH-4 trial is the readout that addresses cardiovascular outcomes and obesity-with-comorbidity populations — the dimension on which retatrutide differentiates clinically from the already-approved tirzepatide. The Phase 2 retatrutide data (published NEJM 2023) showed weight-loss magnitude superior to tirzepatide. The Phase 3 question was whether the magnitude advantage holds at scale, in patients with metabolic comorbidities, and across longer treatment duration.
TRIUMPH-1 through TRIUMPH-3 addressed weight-loss-only populations across different baseline characteristics. TRIUMPH-4 adds the comorbidity dimension. TRIUMPH-5 (still partly enrolling at the time of this writing) addresses the cardiovascular-outcomes endpoint specifically — the bar that GLP-1-class drugs are increasingly held to following the SELECT trial precedent for semaglutide.
The headline Phase 3 retatrutide weight-loss figure consistent across the published TRIUMPH readouts: ~24% mean body-weight reduction at the highest tested dose at 48 weeks, holding from the Phase 2 ceiling. This is approximately 2–4 percentage points above the highest-dose tirzepatide ceiling in the SURMOUNT trials.
| Compound | Mechanism | Peak weight loss (Phase 3, 48-week, top dose) | |---|---|---| | Semaglutide (Wegovy) | GLP-1 mono-agonist | ~15% | | Tirzepatide (Zepbound) | GLP-1 + GIP dual-agonist | ~21% | | Retatrutide | GLP-1 + GIP + glucagon triple-agonist | ~24% |
Three structural observations on the readout:
The curve does not plateau as early. The retatrutide weight-loss trajectory in the TRIUMPH trials continues sloping down past the 48-week mark in the open-label-extension data. Tirzepatide and semaglutide show flatter slopes by the 40-week mark in their respective Phase 3 readouts. The mechanism explanation is the third receptor (glucagon), which contributes to energy expenditure rather than just appetite suppression.
The side-effect profile is class-similar, with one specific addition. GI side effects (nausea, vomiting, dose-titration tolerability) are broadly comparable to the GLP-1 mono- and dual-agonists. The glucagon-receptor activity introduces a heart-rate elevation signal that is being monitored carefully in the TRIUMPH-4 and TRIUMPH-5 readouts — modest in magnitude (1–3 bpm above baseline across reported populations) but distinct from the other GLP-1-class compounds.
Tolerability scales with titration discipline. The trial protocols use slower dose-titration schedules than were typical in earlier GLP-1 Phase 3 programs. Discontinuation rates due to adverse events in the published Phase 3 readouts are in line with tirzepatide SURMOUNT figures, which is meaningful given the larger weight-loss effect.
Three categories of question that the trial readouts have not answered as of April 2026.
Long-term durability beyond 88 weeks. The longest published TRIUMPH readout extends to 88 weeks. Whether the weight-loss trajectory continues past 100+ weeks, or whether it plateaus as the glucagon-receptor adaptation catches up to the mechanism, is not yet in the public record.
Cardiovascular outcomes superiority. TRIUMPH-5 is the trial that addresses this directly, and as of April 2026 the headline endpoint data is not yet published. The interim safety readouts have been acceptable; the efficacy readout against placebo for major adverse cardiovascular events is the bar GLP-1-class drugs face for a label that supports cardio-protective indications.
Special populations. Pediatric, hepatic-impairment, and pregnant populations are not covered by the published TRIUMPH program. These are typical post-approval study commitments, not Phase 3 program exclusions.
The Eli Lilly investor communications through Q1 2026 indicated a 2026 FDA submission target for retatrutide. As of this writing (May 2026), the submission timing is current-quarter or near-quarter. Two paths from here:
Path A — submission and standard review (12-month timeline). A mid-2026 submission with standard review puts a possible approval decision in mid-2027. The label would likely follow the tirzepatide pattern (chronic weight management in adults with obesity or overweight with weight-related comorbidities). Tirzepatide's Wegovy and Zepbound branding precedent suggests the brand version of retatrutide enters market in 2027.
Path B — submission and priority review (6-month timeline). Less likely given the size of the trial program but possible if the TRIUMPH-5 cardiovascular readout is sufficiently favorable. This path shifts the approval-decision window into late 2026 or early 2027.
The buyer-side implications are bounded. For research-peptide buyers, the regulatory state in May 2026 remains: retatrutide is not FDA-approved, no compounded version is legally available (retatrutide is not on the 503A compounding pathway and not in a brand-product shortage exemption), and any retatrutide obtained for human use is unsupervised. The cleanest legal route remains participation in the TRIUMPH-5 trial or successor trials where they remain enrolling.
For the legal compounded-GLP-1 market, the TRIUMPH program data is indirect news. The April 2026 PCAC reaffirmation (see our enforcement timeline) maintains the compounding restrictions on the GLP-1 class. A brand-approved retatrutide in 2027 does not change that picture; it adds a brand product to the legal-prescription channel without opening the compounding channel.
This article is a literature read on the trial program. It is deliberately not a buyer's guide to research-peptide retatrutide. We do not link to or recommend any research-peptide vendor for this compound, regardless of audit tier. The reasoning:
New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.